{"id":"W3030820428","doi":"10.1200/jco.2020.38.15_suppl.8511","title":"Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"AbbVie","keywords":"Daratumumab; Medicine; Venetoclax; Dexamethasone; Lenalidomide; Internal medicine; Bortezomib; Ven; Multiple myeloma; Refractory (planetary science); Adverse effect; Gastroenterology; Oncology; Pharmacology; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00534678,0.0006956868,0.002124716,0.0004290904,0.0003232947,0.00149869,0.0009570066,0.0009205224,0.003021482],"category_scores_gemma":[0.003462292,0.0005219621,0.002282311,0.00108175,0.000413581,0.0007378855,0.0003900907,0.001670313,0.0005469598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001237443,"about_ca_system_score_gemma":0.001866058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001542998,"about_ca_topic_score_gemma":0.005343699,"domain_scores_codex":[0.9978514,0.001225272,0.0001879485,0.0002808291,0.0002972075,0.000157311],"domain_scores_gemma":[0.9957949,0.00109564,0.001535521,0.0003103467,0.0003566571,0.0009069875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6398188,0.007303152,0.1452839,0.001777521,0.01339932,0.0005641835,0.0002408356,0.00359643,0.02294655,0.0003412516,0.01249075,0.1522373],"study_design_scores_gemma":[0.2904479,0.146902,0.5071747,0.000259676,0.01846377,0.001651618,0.0001682227,0.002626942,0.00488684,0.0004067278,0.02691117,0.0001003744],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9635494,0.01527844,0.0009973162,0.00124726,0.0002037901,0.001670276,0.01285672,0.000155238,0.004041539],"genre_scores_gemma":[0.9693886,0.003416969,0.002150813,0.001757983,0.0001991877,0.0006513028,0.02096679,0.00005272826,0.001415642],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00534678,"threshold_uncertainty_score":0.0282768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07932042657040811,"score_gpt":0.432142852572068,"score_spread":0.3528224260016599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}